Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025 TEL AVIV, Israel and WALTHAM, Mass., Sept. 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the launch of Mobilization Matters, a digital resource for people with multiple myeloma who are preparing for stem cell collection for an autologous stem cell transplant ...

BioLineRx Ltd. (NASDAQ:BLRX) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2024 Financial Results Conference Call. [Operator Instructions]. Following managem ...

Core Insights - BioLineRx Ltd. has successfully secured formulary placement for its APHEXDA® product among the top 80 transplant centers, representing approximately 37% of stem cell transplant procedures, exceeding its quarterly goal and aiming for 60% by the end of 2024 [1][2][4] - The company has doubled the number of centers ordering APHEXDA in the second quarter, indicating strong commercial momentum and recognition of its value compared to other mobilization agents [2][4] - BioLineRx has entered into a clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization in gene therapies for sickle cell disease [3][4] APHEXDA Launch Updates - The formulary placement at transplant centers has surpassed the company's goal, with a target of reaching 60% by year-end 2024 [1][4] - The number of centers ordering APHEXDA has doubled in the second quarter compared to the first quarter, contributing to a 100% quarter-over-quarter net revenue growth [4][6] - The ongoing clinical trial collaboration with St. Jude Children's Research Hospital aims to evaluate APHEXDA for stem cell mobilization in patients with sickle cell disease [3][4] Clinical Portfolio Updates - A Phase 1 clinical trial is being conducted at Washington University in St. Louis to evaluate motixafortide for stem cell mobilization in sickle cell disease, with initial data expected in 2025 [3][4] - Positive biopsy data from the CheMo4METPANC Phase 2b clinical trial for pancreatic cancer has shown a significant increase in CD8+ T-cell density [5] - The company anticipates the initiation of a pivotal clinical trial in China for motixafortide in combination with standard chemotherapy for metastatic pancreatic cancer in 2025 [5] Financial Results - Total revenue for the second quarter of 2024 was $5.4 million, a significant increase from no revenue recorded in the same period of 2023 [6] - The cost of revenue for the quarter was $0.9 million, primarily reflecting amortization of intangible assets and royalties on APHEXDA sales [6] - The company reported a net income of $0.5 million for the second quarter of 2024, compared to a net loss of $18.5 million in the same period of 2023 [6][15] Cash Position - As of June 30, 2024, BioLineRx had cash, cash equivalents, and short-term bank deposits totaling $40.1 million, which is expected to fund operations into 2025 [6][17]

BioLineRx Ltd. (NASDAQ:BLRX) Q1 2024 Earnings Call Transcript May 28, 2024 8:30 AM ET Company Participants Conference Call Participants Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2024 Financial Results Conference Call. All participants are presently in a listen-only mode. Following management's formal presentation, instructions will be given for the question-and-answer session. I would now like to turn over the call to John Lacey, Head of Investor Relations and C ...

Core Insights - BioLineRx Ltd. reported steady growth in the adoption of APHEXDA® in its first full quarter post-approval, with formulary placement secured at institutions representing approximately 26% of stem cell transplant procedures performed, on track to reach 35% by the end of Q2 2024 [1][2][6] - The company announced new data from its ongoing Phase 2b pancreatic cancer clinical trial collaboration with Columbia University, highlighting significant increases in CD8+ T-cell density in tumors from treated patients [3][8] - BioLineRx completed debt and equity financing totaling $26 million to support the U.S. commercialization of APHEXDA and advance lifecycle expansion activities [1][5] APHEXDA Launch Updates - Among the top 80 transplant centers, BioLineRx has secured formulary placement at institutions representing approximately 26% of stem cell transplant procedures, aiming for 35% by the end of Q2 and 60% by year-end 2024 [6] - The company received "pass through" status from the Centers for Medicare and Medicaid Services (CMS), ensuring separate reimbursement for APHEXDA when administered in the hospital outpatient setting [6] Clinical Portfolio Updates - In pancreatic cancer, BioLineRx is advancing its major pipeline program, with new data presented at the ASCO 2024 Annual Meeting showing promising results from the pilot phase of the Phase 2 PDAC trial [3][8] - The company is also pursuing motixafortide's potential in gene therapy for sickle cell disease, with initial data expected in the second half of 2024 from a collaboration with Washington University [4][8] Financial Results - For the first quarter ended March 31, 2024, total revenue was $6.9 million, reflecting a portion of the upfront payment and milestone payment from the Gloria Biosciences license agreement, along with $0.9 million from APHEXDA product sales [9] - The net loss for the quarter was $0.7 million, a significant reduction from $12.2 million in the same period of 2023, aided by $4.5 million in non-cash income related to warrant revaluation [10][9] - As of March 31, 2024, the company had cash, cash equivalents, and short-term bank deposits totaling $28.2 million, which is expected to fund operations into 2025 [10][9]

Company Overview - BioLineRx Ltd. is a commercial stage biopharmaceutical company focused on developing life-changing therapies in oncology and rare diseases [4] - The company's first approved product is APHEXDA® (motixafortide), indicated for stem cell mobilization for autologous transplantation in multiple myeloma in the U.S. [4] - BioLineRx is advancing a pipeline of investigational medicines targeting sickle cell disease, pancreatic cancer, and other solid tumors [4] Financial Results Announcement - BioLineRx will release its unaudited financial results for the quarter ended March 31, 2024, on May 28, 2024, before U.S. markets open [1] - A conference call will be held at 8:30 a.m. EDT featuring remarks by CEO Philip Serlin [2] Conference Call Access - To access the conference call, dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally [3] - A live webcast and replay will be available on the company's website, with a replay accessible approximately two hours after the live call [3]

Core Points - BioLineRx Ltd. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as the closing bid price for its American Depositary Shares (ADSs) has been below USD $1.00 for 30 consecutive trading days [1][2] - The company has a grace period of 180 calendar days, until November 11, 2024, to regain compliance with the minimum bid price [3] - If the bid price reaches or exceeds USD $1.00 for at least 10 consecutive business days before the deadline, Nasdaq will notify the company of compliance [3] - Should the company fail to regain compliance by the deadline, it may be eligible for an additional 180 days to cure the deficiency if it meets other listing requirements [4] - The company's business operations remain unaffected by the notification, and it will continue to monitor the bid price of its ADSs [5] Company Overview - BioLineRx is a commercial stage biopharmaceutical company focused on developing therapies for oncology and rare diseases [7] - The company's first approved product is APHEXDA® (motixafortide), indicated for stem cell mobilization in multiple myeloma [7] - BioLineRx is advancing a pipeline of investigational medicines targeting sickle cell disease, pancreatic cancer, and other solid tumors [7]

- Presentation Today, Monday, May 6, 2024 in Atlanta, Georgia  - TEL AVIV, Israel, May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Resear ...

-  Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sickle cell disease, and motixafortide metastatic pancreatic cancer program - TEL AVIV, Israel, April 10, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has drawn-down the second tranche of $20 million under its previously announced $40 millio ...

TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 A ...